Comparative Pharmacology
Head-to-head clinical analysis: CIMZIA versus ENBREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIMZIA versus ENBREL.
CIMZIA vs ENBREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Certolizumab pegol is a recombinant, humanized antibody Fab' fragment conjugated to polyethylene glycol (PEG) that binds and neutralizes human tumor necrosis factor alpha (TNFα), preventing its interaction with cell surface TNF receptors (TNFR p55 and p75). It also modulates immune responses by inhibiting TNFα-induced pro-inflammatory cytokine production and adhesion molecule expression.
Tumor necrosis factor (TNF) inhibitor; etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of human TNF receptor p75 linked to the Fc portion of human IgG1. It binds to soluble and membrane-bound TNF, thereby blocking TNF-mediated inflammatory responses.
400 mg subcutaneously at weeks 0, 2, and 4, then 200 mg every 2 weeks or 400 mg every 4 weeks.
50 mg subcutaneous injection once weekly
None Documented
None Documented
14 days (range 11-17 days) following subcutaneous administration; supports every 2-week or monthly dosing intervals.
Approximately 102 hours (range 68–170 hours) after subcutaneous administration in adults; prolonged in elderly and patients with renal impairment; supports every 2-week dosing.
Primarily eliminated via reticuloendothelial system and proteolytic catabolism; no significant renal or biliary excretion. Clinical pharmacokinetic studies show no dose adjustment needed in renal impairment.
Renal: negligible; Biliary/Fecal: not significantly eliminated; primarily degraded via proteolysis into amino acids.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor